Standardized Field Test for Marijuana Impairment II

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-25

Study Completion Date

2023-08-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research responds to NHTSA's request with a proposal to increase our understanding of smoked cannabis' (CNB's) acute effects on driving-relevant cognition and simulated driving performance, the persistence of these deficits over the hours after use, and the influence of prior experience with CNB on these effects. This extension study will aim to further investigate marijuana impaired behavior, using a similar design to our previous NHTSA Examine the Feasibility of a Standardized Field Test for Marijuana Impairment and the prior NIDA Neuroscience of Marijuana-Impaired Driving award, that used similar techniques and measures to quantify marijuana impaired automobile driving. We will be utilizing tasks and assessments that were shown to be strong indicators for cognitive and driving impairment in our NHTSA study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations

NCT03191084

Marijuana Impairment

COMPLETED EARLY_PHASE1

Examine the Feasibility of a Standardized Field Test for Marijuana and Alcohol Impairment: Laboratory Evaluations

NCT04856566

Marijuana Impairment Alcohol Impairment

COMPLETED EARLY_PHASE1

Neuroscience of Marijuana Impaired Driving

NCT02757313

Marijuana Impairment

COMPLETED PHASE1

The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking

NCT02849587

Cannabis Intoxication

COMPLETED PHASE1/PHASE2

Novel Approaches to Assessing Cannabis Impaired Driving (NAACID)

NCT06255054

Cannabis Use

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proposed study was based upon a careful and thorough review of the scientific literature describing CNB effects on cognitive test performance and driving, as well as current state-of-knowledge on the sensitivity of biological assays for identifying recent CNB use. The study will carefully characterize the persistence of CNB's acute effects on cognitive test performance and driving over a several-hour time span. This will allow us to identify the point at which any effects of CNB intoxication driving-related cognitive tests, and driving performance cannot be distinguished from normal, i.e., the first step towards establishing standards for legal and social policy. The data obtained from simulated driving, cognitive tests, and biological assays of THC will be used in analyses aimed at identifying what tests or combination of tests predict both recent use and driving impairment risk.

This study will consist of 2 days (screening visit and dose visit). In a non-randomized, single blinded study, we will dose participants with placebo and high THC marijuana, about an hour apart, using paced inhalation through a vaporizer, an efficient means of delivering a standard THC dose. Participants will be told that the order they receive the doses will be random but they will always receive the placebo first, followed by the high dose. This will allow for standardization across all subjects and comparative values between placebo and drug. After inhaling the placebo dose, participants will be asked to complete one round of cognitive testing and a shortened version of the driving simulator (10 mins vs 30 mins). Approximately one hour post placebo dose, subjects will be administered high THC marijuana. Following this dosing, we will assess impairment through cognitive testing as well as a simulated driving test and neuropsychological tests. Samples of blood will also be collected at multiple time points throughout the study visits to be measured for THC concentration and its metabolites. This allows clarification between the relationship of impairment, as well as subjective and objective intoxication, and levels of THC and it's metabolites in the users system.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Marijuana Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo Marijuana

Placebo Marijuana will be administered.

Group Type EXPERIMENTAL

Placebo THC

Intervention Type DRUG

Marijuana flower with no THC

Medium THC Marijuana

Medium THC marijuana will be administered.

Group Type EXPERIMENTAL

Medium THC

Intervention Type DRUG

Marijuana flower with medium THC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medium THC

Marijuana flower with medium THC

Intervention Type DRUG

Placebo THC

Marijuana flower with no THC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-55 yrs/ old
* Current driver's license and history of repeated highway vehicle driving experience (at least 2 years)
* Recent, recurrent CNB use and felt high when used
* Able to read, speak, and understand English
* Able and willing to provide written informed consent, and willing to commit to the study protocol

Exclusion Criteria

* Current marijuana tolerance, desire to cut down, or cravings to use during periods of abstinence
* New CNB users who have not used at least once during their lifetime.
* Positive screen for drug and alcohol (except THC) on test day will result in rescheduling the appointment
* Former CNB users who are abstaining
* Pregnancy, breastfeeding, and ineffective birth control methods.
* History of adverse psychological or medical effects following cannabis use
* serious medical, neuro-ophthalmological, or neurological illness (i.e. cancer, seizure disorders, encephalopathy)
* History of head trauma with loss of consciousness \> 30 minutes or concussion lasting 30 days.
* IQ \<80 on the Wechsler Abbreviated Scale of Intelligence
* Inability to comprehend written instructions using the WRAT 4 reading achievement test
* Any medical/neurological condition that could compromise neurocognitive performance (i.e. epilepsy, multiple sclerosis, fetal alcohol syndrome)
* Uncontrolled, persistent high blood pressure
* Anyone deemed unsafe to study personnel for any reason

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes